Flezurafenib

Flezurafenib is an investigational new drug that is being evaluated by Jazz Pharmaceuticals for the treatment of cancers that are driven by oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Flezurafenib is an investigational new drug that is being evaluated by Jazz Pharmaceuticals for the treatment of cancers that are driven by oncogenic mutations that activate the RAS-RAF-MAPK signaling pathway. It acts as a rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. As of January 2025, flezurafenib has reached Phase 1 clinical trials, where it is being evaluated for the treatment of advanced solid tumors.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1362705054 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001362705054 · captured 2026-07-05 · ledger · version history

Cite this page as: encyclopegia.org, “Flezurafenib”, snapshot enwiki-001362705054. https://encyclopegia.org/a/flezurafenib

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.